IVPost
FDA approves first tests to screen for tickborne parasite in whole blood and plasma to protect the U.S. blood supply
- Details
- Written by Megan McSeveney
- Category: Latest News
The U.S. Food and Drug Administration today approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay (AFIA), for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, and the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples. These tests are intended to be used as donor screening tests on samples from individual human donors, including volunteer donors of whole blood and blood components, as well as living organ and tissue donors.
NIAID scientists assess transmission risk of familial human prion diseases to mice
- Details
- Written by Ken Pekoc
- Category: Latest News
Familial human prion diseases are passed within families and are associated with 34 known prion protein mutations. To determine whether three of the unstudied mutations are transmissible, scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, exposed research mice to brain samples from three people who died from a familial prion disease. After observing the mice for about two years, they found two of the mutations, Y226X and G131V, are transmissible.
High uptake and use of vaginal ring for HIV prevention observed in open-label study
- Details
- Written by Laura S. Leifman
- Category: Health News
Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to an interim analysis of study data. In addition, the rate of HIV infection among participants in the open-label study, which has no placebo arm for comparison, is half of what might be expected in the absence of the ring, according to mathematical modeling that has significant limitations.
Broadly neutralizing antibody treatment may target viral reservoir in monkeys
- Details
- Written by Judith Lavelle
- Category: Latest News
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed the virus for six months without additional treatment, according to scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapy may have targeted the viral reservoir - populations of long-lived, latently infected cells that harbor the virus and that lead to resurgent viral replication when suppressive therapy is discontinued.
Contact lenses that deliver drugs directly to the eye win health care prize
- Details
- Written by Rob Matheson
- Category: Latest News
A team from a Harvard Medical School affiliate saw its way clearly to victory at last night’s MIT Sloan Healthcare Innovation Prize competition, with contact lenses that deliver medications directly to the eye over days or weeks.
2018 Conference on Retroviruses and Opportunistic Infections
- Details
- Written by IVPost
- Category: Medical News
A new CDC analysis suggests HIV prevention pill is not reaching most Americans who could benefit – especially people of color.
Page 28 of 50